Home > Compound List > Product Information
Tiagabine_Molecular_structure_CAS_115103-54-3)
Click picture or here to close

Tiagabine

Catalog No. DB00906 Name DrugBank
CAS Number 115103-54-3 Website http://www.ualberta.ca/
M. F. C20H25NO2S2 Telephone (780) 492-3111
M. W. 375.548 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 782

SYNONYMS

IUPAC name
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
IUPAC Traditional name
tiagabine
Brand Name
Gabitril
Synonyms
Tiagabina [INN-Spanish]
Tiagabinum [INN-Latin]

DATABASE IDS

CAS Number 115103-54-3
PubChem CID 60648
PubChem SID 46505560

PROPERTIES

Hydrophobicity(logP) 2.6

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Indication For the treatment of partial seizures
Pharmacology Tiagabine is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells.
Toxicity mptoms most often accompanying tiagabine overdose, alone or in combination with other drugs, have included: seizures including status epilepticus in patients with and without underlying seizure disorders, nonconvulsive status epilepticus, coma, ataxia, confusion, somnolence, drowsiness, impaired speech, agitation, lethargy, myoclonus, spike wave stupor, tremors, disorientation, vomiting, hostility, and temporary paralysis. Respiratory depression was seen in a number of patients, including children, in the context of seizures.
Affected Organisms
Humans and other mammals
Biotransformation Tiagabine is likely metabolized primarily by the 3A isoform subfamily of hepatic cytochrome P450.
Absorption Tiagabine is nearly completely absorbed (>95%).
Half Life 7-9 hours
Protein Binding 96%
Elimination Approximately 2% of an oral dose of tiagabine is excreted unchanged, with 25% and 63% of the remaining dose excreted into the urine and feces, respectively, primarily as metabolites.
Clearance * 109 mL/min [Healthy subjects]
External Links
Wikipedia
RxList
Drugs.com

REFERENCES